№ lp_1_10764
File format: docx Character count: 3781 File size: 77 KB
Recommendations report detailing specialist prescribing guidelines, treatment protocol, cost, and monitoring plan for the use of MV140 Uromune in adults with recurrent lower urinary tract infections.
Date: 19 November 2025
Organization: Medicines, Formulary, and Guidelines Group
Location: Humber and North Yorkshire, UK
Document type: Consultation summary / Recommendations
Drug: MV140 Uromune Sublingual vaccine spray
Indication: Recurrent lower urinary tract infections in adults
Formulary status: Red – Specialist urology only
Treatment protocol: 2 sprays sublingually once daily for 3 months, possible rechallenge after 18 months
Cost per patient: £297.50
Monitoring: Telephone reviews at 1, 3, 6, 9, 12 months; Consultant Urologist review at 6 and 12 months
Professional target audience: NHS healthcare professionals
Source: HNY APC Professional Secretariat, Regional Drug and Therapeutics Centre
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
SUMMARY OF RECOMMENDATIONS FOR HNY-WIDE CONSULTATION
Year: 2025
Region / City: Humber and North Yorkshire
Topic: Medicines and formulary recommendations
Document Type: Recommendations summary
Author: Medicines, Formulary, and Guidelines Group
Target Audience: Healthcare professionals
Period of Validity: Until December 2026
Approval Date: 19 November 2025
Date of Changes: Not specified
Contextual description: A source document summarizing the recommendations made by the Medicines, Formulary, and Guidelines Group regarding various drug formulary updates and changes for the Humber and North Yorkshire region.
Summary of Recommendations for HNY-Wide Consultation, 17 December 2025
Year: 2025
Region: Humber and North Yorkshire, UK
Subject: Medicines formulary and NICE guidance recommendations
Document type: Professional guidance / summary report
Organization: Humber and North Yorkshire Area Prescribing Committee (HNY APC)
Author: Medicines, Formulary, and Guidelines Group
Intended audience: NHS healthcare professionals
Key drugs discussed: Sildenafil, Darolutamide, Abiraterone, Cabotegravir
Decision criteria: NICE technology appraisals, cost-effectiveness, commissioning status
Date of issue: 17 December 2025
Links: https://humberandnorthyorkshire.org.uk/area-prescribing-committee-apc/apc-consultations/
Context: Official NHS report summarizing formulary decisions, NICE appraisal outcomes, and local prescribing guidance for healthcare professionals.
Topics: MV140 Uromune HNY-Wide